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Abstract Ghrelin is a novel gastrointestinal peptide that stim-
ulates growth hormone secretion, food intake, and body weight
gain. Increased ghrelin secretion has been reported in such neg-
ative energy states as starvation and low body weight. We in-
vestigated the dynamics of ghrelin in rats with streptozotocin-
induced diabetes, because they present reduced body weight and
hyperphagia. The plasma ghrelin levels and gastric preproghre-
lin mRNA expression levels of the diabetic rats increased sig-
ni¢cantly and their gastric ghrelin levels decreased signi¢cantly.
Negative energy balance may enhance preproghrelin mRNA
expression and ghrelin secretion into the bloodstream.
$ 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Ghrelin is a novel growth hormone secretagogue recently
isolated from human and rat stomach [1]. It possesses unique
n-octanoyl modi¢cation at the third serine residue that is es-
sential to ghrelin’s physiological activities. The physiological
role of ghrelin is to stimulate growth hormone release, food
intake [2], and gastric motility [3], and in both humans and
rodents, negative energy balance states, such as starvation or
the low body weight in cachexia or anorexia nervosa, have
been reported to increase plasma ghrelin levels [4^8]. Many
tissues express preproghrelin mRNA [9], but the gastric fun-
dus has the highest levels of expression [10]. A-like cells,
which are mainly present in the gastric fundus, have been
reported to secrete ghrelin [11].
Streptozotocin (STZ) is an antibiotic that induces diabetes
by damaging insulin-secreting cells in the pancreas, and rats
with STZ-induced diabetes exhibit reduced body weight, hy-
perphagia, hyperglycemia, and hypoinsulinemia [12,13]. No
studies, however, have addressed the dynamics of ghrelin
in rats with STZ-induced insulin-dependent diabetes. The
present study investigated the relation between ghrelin dynam-
ics and secretory regulation in rats with STZ-induced diabetes
by means of radioimmunoassay (RIA), real-time reverse tran-
scription polymerase chain reaction (RT-PCR), and immuno-
histochemical techniques.
2. Materials and methods
2.1. Animal procedures
All animal experiments and procedures were approved by the Keio
University Animal Research Committee (No. 001022). Diabetes was
induced in 8-week-old male Wistar rats by intraperitoneal injection of
STZ (60 mg/kg) after an overnight fast (n=11); control rats were
injected with physiological saline (n=9). All animals were allowed
free access to tap water and a standard pellet rat diet (CE-2, Clea,
Tokyo, Japan). Four weeks later, the rats were killed under ether
anesthesia after a 16 h fast. The stomachs of the rats were excised,
cut along the greater curvature, and rinsed with isotonic saline. The
duodenums and ascending colons were also removed. Separately, we
performed the same experiment on three animal groups which con-
sisted of control rats (n=6), rats with STZ-induced diabetes (n=6)
and insulin-treated diabetic rats (n=5). They were given free access to
food. Insulin-treated diabetic rats were given neutral protamine Ha-
gedorn human insulin (7 U/animal) by subcutaneous injection, begin-
ning 1 week after the STZ injection.
2.2. Blood and hormonal assays
Serum glucose values were measured by the glucose dehydrogenase
method. Serum insulin, serum insulin-like growth factor-1 (IGF-1),
and serum growth hormone (GH) levels were measured with commer-
cial immunoradiometric assays (rat insulin RIA kit, Linco Research,
St. Charles, MO, USA; rat IGF-1 RIA kit, Diagnostic Systems Lab-
oratories, Webster, TX, USA; and rat Growth Hormone Assay sys-
tem, Amersham Biosciences, Piscataway, NJ, USA).
2.3. Ghrelin RIA
The two RIAs of gastric and plasma ghrelin levels were performed
as described previously [14,15]. Gastric and plasma ghrelin were mea-
sured by RIAs using two polyclonal rabbit antibodies, one raised
against the N-terminal [1^11] (Gly1^Lys11) fragment and the other
raised against the C-terminal [13^28] (Gln13^Arg28) fragment of rat
ghrelin. The anti-ghrelin antisera do not recognize other enteric pep-
tides. Ghrelin values obtained by N-terminal RIA using an anti-ghre-
lin [1^11] antiserum speci¢cally represent the active, n-octanoylated
ghrelin. The values obtained by C-terminal RIA using an anti-ghrelin
[13^28] antiserum represent the total ghrelin concentration, including
the inactive des-acyl ghrelin. The respective intra- and inter-assay
coe⁄cients of variation were 3% and 6% for the N-terminal RIA
and 6% and 9% for the C-terminal RIA. For peptide extraction, rat
stomachs were boiled for 5 min in a 10-fold volume of water to
inactivate intrinsic proteases, adjusted with 1 M acetic acid after cool-
ing, and homogenized with a Polytron mixer. The supernatants were
lyophilized and resuspended in assay bu¡er for the ghrelin RIAs. The
tissue ghrelin extraction e⁄ciency of this procedure is more than 95%.
Whole blood samples were collected with EDTA (1 mg/ml blood) and
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aprotinin (70 Wg/ml blood), and the plasma passed through a C18
Sep-Pak cartridge (Waters, Milford, MA, USA). The cartridges
were washed and eluted with tri£uoroacetic acid, acetonitrile and
distilled water; and the eluate (a 100 Wl equivalent of plasma) was
lyophilized and subjected to ghrelin RIAs. The extraction e⁄ciency
for plasma ghrelin was approximately 90%.
2.4. Real-time RT-PCR
Total RNA was extracted from the stomach, duodenum, and as-
cending colon of the rats with the RNeasy Mini Kit (Qiagen, Hilden,
Germany). A TaqMan0 quantitative real-time RT-PCR was used to
detect preproghrelin mRNA and glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) mRNA (Platinum Quantitative RT-PCR Ther-
moScript One-Step System, Invitrogen, Carlsbad, CA, USA).
The following primers were used to amplify the preproghrelin
mRNA: forward primer (ghrelin-F), 5P-GGA ATC CAA GAA
GCC ACC AGC-3P ; reverse primer (ghrelin-R), 5P-GCT CCT GAC
AGC TTG ATG CCA-3P. The following TaqMan probe was used for
preproghrelin: 5P-FAM-AAC TGC AGC CAC GAG CTC TGG
AAG GC-TAMRA-3P.
As an internal control, the following primers were used to amplify
GAPDH mRNA: forward primer (GAPDH-F), 5P-TTC AAC GGC
ACA GTC AAG GC-3P ; reverse primer (GAPDH-R), 5P-GCC TTC
TCC ATG GTG GTG AAG-3P. The following TaqMan probe was
used for GAPDH: 5P-FAM-CCC ATC ACC ATC TTC CAG GAG
CGA GA-TAMRA-3P.
The PCR cycling parameters were: 30 min at 50‡C and 5 min at
95‡C followed by 40 cycles of 15 s at 95‡C and 60 s at 60‡C. The
ampli¢cations were performed with a real-time PCR system (ABI
Prism 7700 Sequence Detection System, PE Applied Biosystems, Nor-
walk, CT, USA). Preproghrelin mRNA expression levels were nor-
malized to the GAPDH mRNA expression levels.
2.5. Immunohistochemistry of ghrelin-immunoreactive cells
Tissue samples were ¢xed in 10% neutralized formalin and em-
bedded in para⁄n. The samples were then sectioned (4^6 Wm thick),
and the sections were allowed to adhere to slides pretreated with a
0.01% aqueous solution of poly-L-lysine. The sections were depara⁄-
nized by heating for 10 min at 70‡C and then hydrated by transferring
the slides through the following solutions: xylene (5 min, U2), 96%
ethanol (3 min, U2), 90% ethanol (3 min, U1), and double-distilled
water (3 min, U1).
After pretreatment with 0.3% hydrogen peroxide and incubation
with normal goat serum, all slices were incubated overnight at 4‡C
with anti-ghrelin [13^28] antiserum (¢nal dilution, 1:10 000) [11]. After
washing with phosphate-bu¡ered saline, the slides were incubated
overnight at 4‡C in the presence of goat biotinylated anti-rabbit
IgG (Vectastain, Vector Laboratories, Burlingame, CA, USA) [11].
The slides were then stained for 10 min at room temperature by the
avidin^biotin^peroxidase complex method (Vectastain Elite ABC kit,
Vector Laboratories) with 0.02% 3,3P-diaminobenzidine tetrahydro-
chloride (Sigma) and 0.006% hydrogen peroxide in 50 mM Tris^
HCl bu¡er solution (pH 7.2) [11]. After dehydration in a graded
alcohol series, the slides were counterstained with hematoxylin.
The stained sections were examined with a light microscope (Eclipse
600, Nikon, Tokyo, Japan) equipped with a 3CCD digital camera
Table 1
Body weight, gastric weight, serum glucose values, serum insulin levels, serum IGF-1 levels and serum GH levels in rats with STZ-induced dia-
betes
Body weight
(g)
Gastric weight
(mg)
Serum glucose
(mg/dl)
Serum insulin
(ng/ml)
Serum GH
(ng/ml)
Serum IGF-1
(ng/ml)
Control rats (n=9) 353.6V 16.1 2145.9V 82.2 136.7V 4.2 0.26V 0.06 6.64V 0.23 1478.9V 137.6
Diabetic rats (n=11) 208.5V 12.6*** 2160.8V 86.0 451.0V 41.6*** 0.06V 0.03** 47.21V 19.14* 449.8V 32.6***
Values are given as meanVS.E.M.
***P6 0.001, **P6 0.01, *P6 0.05 as compared to control value.
Fig. 1. Plasma ghrelin levels as measured by RIA (a: total ghrelin, b: active ghrelin) in fasted control rats (Cont., open column: n=9) and
fasted rats with STZ-induced diabetes (STZ, closed column: n=11). Total ghrelin was detected by C-terminal RIA with an anti-ghrelin [13^28]
antiserum. Active ghrelin was detected by N-terminal RIA with an anti-ghrelin [1^11] antiserum. The plasma total and active ghrelin levels in-
creased signi¢cantly in the fasted diabetic rats. Gastric ghrelin levels measured by RIA (c: total ghrelin, d: active ghrelin) in fasted control rats
(open column: n=9) and fasted diabetic rats (closed column: n=11). The gastric total and active ghrelin levels of the fasted diabetic rats de-
creased signi¢cantly. ***P6 0.001, **P6 0.01, *P6 0.05 compared with the fasted control rats.
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(C7780, Hamamatsu Photonics, Hamamatsu, Japan), and digital color
images were stored as PSD ¢les with Adobe Photoshop 7.0 software.
The hematoxylin- and/or diaminobenzidine tetrahydrochloride-stained
nuclei in the regions of interest were counted with a particle analysis
program (Ultimage Pro. 2.6.4; Alliance Vision, France). The density
of the ghrelin-immunoreactive cells (Dghrelin) was calculated by using
the following formula:
Dghrelin ¼ ðNg=N tÞU100 ð%Þ
where Ng represents the number of ghrelin-immunoreactive cells in the
region of interest and Nt represents the total number of cells in the
region of interest.
2.6. Statistical analysis
All data are expressed as meansVS.E.M. The data were analyzed
by one-way analysis of variance followed by Sche¡e¤’s multiple com-
parison tests, and a P value of 6 0.05 was considered to be statisti-
cally signi¢cant.
3. Results
The body weight of the diabetic rats decreased signi¢cantly
(P6 0.001) and their serum glucose values increased signi¢-
cantly (P6 0.001), compared to the values in the control rats
(Table 1). Their serum insulin levels decreased signi¢cantly
(P6 0.01). Although the serum GH levels of the diabetic
rats increased signi¢cantly (P6 0.05), their serum IGF-1 levels
decreased signi¢cantly (P6 0.001) (Table 1). The wet weight
of stomach of the diabetic rats did not di¡er from that of the
controls (Table 1).
The plasma total (Fig. 1a) and active (Fig. 1b) ghrelin levels
of the diabetic rats increased signi¢cantly (total ghrelin,
P6 0.01; active ghrelin, P6 0.05), compared with those of
the control rats. The plasma total ghrelin levels of the diabetic
rats correlated signi¢cantly with their serum GH levels (r=
0.81, P6 0.01) and with their serum IGF-1 levels (r=30.58,
P6 0.01).
The gastric total (Fig. 1c) and active (Fig. 1d) ghrelin levels
of the diabetic rats decreased signi¢cantly (total ghrelin,
P6 0.001; active ghrelin, P6 0.05), compared with the levels
in the controls, and their gastric total ghrelin levels corre-
lated signi¢cantly with their serum IGF-1 levels. (r=0.65,
P6 0.01).
The preproghrelin mRNA expression levels in the stomach
increased signi¢cantly (P6 0.001) in the diabetic rats com-
pared with the controls. The preproghrelin mRNA expression
levels in the duodenum and colon of the diabetic rats were not
signi¢cantly di¡erent from those in the controls (Fig. 2).
The number of ghrelin-immunoreactive cells in the gastric
fundus of the diabetic rats decreased signi¢cantly compared
with the control rats (Fig. 3a), suggesting an increase of empty
cells in the stomachs of the diabetic rats. The ratio of ghrelin-
immunoreactive cells to the total number of cells in the tissue
samples from the gastric fundus of the diabetic rats tended to
be smaller, but the di¡erence was not statistically signi¢cant
compared to the control rats (P=0.054; Fig. 3b).
In the experiments with rats allowed to feed ad lib, the
plasma total ghrelin levels increased signi¢cantly in diabetic
rats (P6 0.05), but insulin treatment tended to attenuate the
increase (P=0.05; Fig. 4a). Although the gastric total ghrelin
levels decreased in the diabetic rats compared with the con-
trols (P6 0.01), insulin treatment signi¢cantly attenuated the
decrease in these levels in the diabetic rats (P6 0.001; Fig.
Fig. 2. Preproghrelin mRNA expression levels in the gastrointestinal
tract of the fasted control rats (open column: n=9) and the fasted
rats with STZ-induced diabetes (closed column: n=11), normalized
to the GAPDH mRNA expression level measured using real-time
RT-PCR. ***P6 0.001 compared with the fasted control rats.
Fig. 3. Analysis of ghrelin-immunoreactive cells in the gastric fun-
dus; ghrelin-immunoreactive cells were detected with an antiserum
for the C-terminal of ghrelin. Number of ghrelin-immunoreactive
cells (a) and density of ghrelin-immunoreactive cells (b) in fasted
control rats (Cont., open column: n=9) and fasted rats with STZ-
induced diabetes (STZ, closed column: n=11). *P6 0.05, compared
with the control rats; 2P=0.054 compared with the fasted control
rats.
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4b). The ratio of gastric active and total ghrelin was unaltered
across these three cohorts (data not shown). Although the
number of ghrelin-immunoreactive cells in the gastric fundus
of the diabetic rats decreased signi¢cantly as compared with
their controls (P6 0.05), insulin treatment signi¢cantly atte-
nuated (P6 0.01) the decrease in the ghrelin-immunoreactive
cells observed in the gastric fundic specimens of the diabetic
rats (Fig. 4c).
4. Discussion
The body weight and serum insulin levels of the STZ-
treated rats decreased signi¢cantly and their blood glucose
values markedly increased. These ¢ndings agree with those
in a previous report [13] and suggest that the STZ injection
had been successful in inducing diabetes mellitus in our cohort
of rats.
Exogenous ghrelin administration has been reported to in-
crease the serum GH levels of rats [16], and the increased
serum GH levels correlated well with the plasma ghrelin levels
in the rats with STZ-induced diabetes (Table 1), the same as
reported in the cachexia associated with chronic heart failure
[6].
The results of the present study in rats with STZ-induced
diabetes clearly demonstrate that the plasma ghrelin levels and
the gastric preproghrelin mRNA expression levels in the stom-
achs of the diabetic rats increased signi¢cantly and their gas-
tric ghrelin levels and numbers of ghrelin-immunoreactive
cells in the gastric fundus decreased signi¢cantly.
No signi¢cant di¡erences in preproghrelin mRNA expres-
sion levels were observed in the colon and duodenum in the
present study, although the second highest levels of preprogh-
relin mRNA expression, ghrelin peptide concentration and
number of ghrelin-immunoreactive cells were found in the
duodenum [11,17,18]. This suggests that the ghrelin-producing
cells in the stomach, not in the duodenum and colon, play a
major role in the increase in plasma ghrelin levels observed in
STZ-induced diabetic rats.
The reversibility of the decreased number of ghrelin-immu-
noreactive cells in the gastric fundus in response to insulin
treatment indicates that the decrease in the labeled cells re-
£ects a decrease in ghrelin content in A-like cells in the stom-
ach, not a decrease of ghrelin-producing A-like cells. The in-
creased plasma ghrelin levels, the decreased gastric ghrelin
levels and the numbers of ghrelin-immunoreactive cells in
the diabetic rats may be due to an increase in ghrelin release
by the stomach into the bloodstream. The content of A-like
cells (ghrelin) might become empty.
Since the body weight of the diabetic rats decreased signi¢-
cantly, and the changes in ghrelin dynamics (plasma ghrelin
levels, gastric ghrelin levels and ghrelin-immunoreactive cell
number in the fundic mucosa) in the diabetic rats are revers-
ible in response to insulin treatment, these changes could be
attributable to negative energy balance states such as low
body weight, not to direct irreversible toxicity of STZ on
the gastric mucosa. Although the mechanism of the signal
pathway that stimulates ghrelin synthesis or secretion remains
unknown, decreased serum IGF-1 levels may play a role in it
since serum IGF-1 levels correlated signi¢cantly with plasma
and gastric total ghrelin.
Negative energy balance might induce a compensatory sig-
nal to up-regulate the levels of preproghrelin mRNA expres-
Fig. 4. Plasma total ghrelin levels measured by RIA in fed control
rats (Cont., open column: n=6), fed STZ-induced diabetic rats
(STZ, closed column: n=6), and fed insulin-treated diabetic rats
(STZ+INS, striped column: n=5) (a). Total ghrelin was detected by
C-terminal RIA with an anti-ghrelin [13^28] antiserum. Although
the plasma total ghrelin levels increased signi¢cantly in the diabetic
rats, insulin treatment tended to attenuate (P=0.05) the increase.
Gastric total ghrelin levels measured by RIA in fed control rats
(open column: n=6), fed diabetic rats (closed column: n=6), and
fed insulin-treated diabetic rats (striped column: n=5) (b). Although
the gastric total ghrelin levels decreased in the fed diabetic rats as
compared with the controls, insulin treatment signi¢cantly attenu-
ated the decrease. Ghrelin-immunoreactive cells in the gastric fundus
were detected with an antiserum for the C-terminus of ghrelin. The
number of ghrelin-immunoreactive cells (c), in fed control rats
(open column: n=6), fed diabetic rats (closed column: n=6), and
fed insulin-treated diabetic rats (striped column: n=5). The number
of ghrelin-immunoreactive cells in the fed STZ-induced diabetic rats
decreased signi¢cantly. *P6 0.05, compared with the fed control
rats; ##P6 0.001, compared with the fed diabetic rats; #P6 0.05,
compared with the fed insulin-treated diabetic rats.
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sion in the stomach and to increase ghrelin generation and
secretion.
In conclusion, ghrelin secretion by the stomach into the
bloodstream increased signi¢cantly in the rats with STZ-in-
duced diabetes suggesting that the negative energy balance in
the STZ-treated rats may have induced the signal to up-reg-
ulate the preproghrelin mRNA expression levels and stimu-
lated ghrelin synthesis as well as secretion by the ghrelin-pro-
ducing cells in the stomach.
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